Clinical Trial Update: Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating belimumab's impact on a BLyS activity signature test in systemic lupus erythematosus, without confounding polypharmac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Belimumab (belimumab)

Snippet

Sponsor: Oklahoma Medical Research Foundation | Conditions: Systemic Lupus Erythematosus | Phase 4 | Status: UNKNOWN